(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape ...
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (VCYT 0.35%) are up 23% over the last week as of market close Thursday, after the compan ...
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and ...
Zacks Investment Research on MSN
Here's how much you'd have if you invested $1000 in Veracyte a decade ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...
While many companies developing blood tests and genomic analyses for cancer are aiming to improve early diagnosis, most of Veracyte’s tests focus on the journey that comes after. Its Decipher Prostate ...
Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equities recorded ...
Veracyte's stock plunge has more to do with valuation than its fundamentals. Its product portfolio and enviable cash position should help continue to grow its revenue by 25% annually. At 16 times this ...
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (NASDAQ: VCYT) are up 23% over the last week as of market close Thursday, after the company reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results